Protein Transfer-mediated Surface Engineering to Adjuvantate Virus-like Nanoparticles for Enhanced Anti-viral Immune Responses

Overview

Journal Nanomedicine

Publisher Elsevier

Specialties Biomedical Engineering
Biotechnology

Date 2015 Mar 11

PMID 25752855

Citations 14

Authors

Jaina M Patel

Min-Chul Kim

Vincent F Vartabedian

Yu-Na Lee

Sara He

Jae-Min Song

Hyo-Jick Choi

Satoshi Yamanaka

Nikhil Amaram

Anna Lukacher

Carlo D Montemagno

Richard W Compans

Sang-Moo Kang

Periasamy Selvaraj

Affiliations

Soon will be listed here.

Abstract

From The Clinical Editor: The inherent problem with current influenza vaccines is that they do not generate effective cross-protection against heterologous viral strains. In this article, the authors described the development of virus-like nanoparticles (VLPs) as influenza vaccines with enhanced efficacy for cross-protection, due to an easy protein transfer modification process.

Citing Articles

(Patho)Physiology of Glycosylphosphatidylinositol-Anchored Proteins II: Intercellular Transfer of Matter (Inheritance?) That Matters.

Muller G, Muller T Biomolecules. 2023; 13(6).

PMID: 37371574 PMC: 10295932. DOI: 10.3390/biom13060994.

Recent Advances and Perspectives of Nanomaterials in Agricultural Management and Associated Environmental Risk: A Review.

Tripathi S, Mahra S, J V, Tiwari K, Rana S, Tripathi D Nanomaterials (Basel). 2023; 13(10).

PMID: 37242021 PMC: 10222951. DOI: 10.3390/nano13101604.

Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged mice.

Park B, Bommireddy R, Chung D, Kim K, Subbiah J, Jung Y Immun Ageing. 2023; 20(1):20.

PMID: 37170231 PMC: 10173218. DOI: 10.1186/s12979-023-00344-w.

Chemical and Synthetic Biology Approaches for Cancer Vaccine Development.

Hossain F, Kandalai S, Zhou X, Zhang N, Zheng Q Molecules. 2022; 27(20).

PMID: 36296526 PMC: 9611187. DOI: 10.3390/molecules27206933.

Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses.

Bommireddy R, Stone S, Bhatnagar N, Kumari P, Munoz L, Oh J Vaccines (Basel). 2022; 10(6).

PMID: 35746552 PMC: 9230705. DOI: 10.3390/vaccines10060944.

References

Grgacic E, Anderson D . Virus-like particles: passport to immune recognition. Methods. 2006; 40(1):60-5. PMC: 7128828. DOI: 10.1016/j.ymeth.2006.07.018. View

Nagarajan S, Selvaraj P . Human tumor membrane vesicles modified to express glycolipid-anchored IL-12 by protein transfer induce T cell proliferation in vitro: a potential approach for local delivery of cytokines during vaccination. Vaccine. 2005; 24(13):2264-74. DOI: 10.1016/j.vaccine.2005.11.045. View

Skountzou I, Quan F, Gangadhara S, Ye L, Vzorov A, Selvaraj P . Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J Virol. 2006; 81(3):1083-94. PMC: 1797543. DOI: 10.1128/JVI.01692-06. View

Quan F, Sailaja G, Skountzou I, Huang C, Vzorov A, Compans R . Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Vaccine. 2007; 25(19):3841-50. PMC: 1973151. DOI: 10.1016/j.vaccine.2007.01.107. View

Bright R, Carter D, Daniluk S, Toapanta F, Ahmad A, Gavrilov V . Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 2007; 25(19):3871-8. DOI: 10.1016/j.vaccine.2007.01.106. View

Ludwig C, Wagner R . Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol. 2007; 18(6):537-45. PMC: 7126091. DOI: 10.1016/j.copbio.2007.10.013. View

Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann M . Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008; 38(5):1404-13. DOI: 10.1002/eji.200737984. View

Wang B, Quan F, Kang S, Bozja J, Skountzou I, Compans R . Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol. 2008; 82(23):11813-23. PMC: 2583664. DOI: 10.1128/JVI.01076-08. View

Cubas R, Zhang S, Kwon S, Sevick-Muraca E, Li M, Chen C . Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother. 2009; 32(2):118-28. PMC: 2717166. DOI: 10.1097/CJI.0b013e31818f13c4. View

10.

Kang S, Yoo D, Lipatov A, Song J, Davis C, Quan F . Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One. 2009; 4(3):e4667. PMC: 2646145. DOI: 10.1371/journal.pone.0004667. View

11.

Haynes J . Influenza virus-like particle vaccines. Expert Rev Vaccines. 2009; 8(4):435-45. DOI: 10.1586/erv.09.8. View

12.

Le Tallec D, Doucet D, Elouahabi A, Harvengt P, Deschuyteneer M, Deschamps M . Cervarix, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions. Hum Vaccin. 2009; 5(7):467-74. DOI: 10.4161/hv.8485. View

13.

Kang S, Song J, Quan F, Compans R . Influenza vaccines based on virus-like particles. Virus Res. 2009; 143(2):140-6. PMC: 2753524. DOI: 10.1016/j.virusres.2009.04.005. View

14.

Hendrikx L, Berbers G, Veenhoven R, Sanders E, Buisman A . IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. Vaccine. 2009; 27(47):6530-6. DOI: 10.1016/j.vaccine.2009.08.052. View

15.

Zhang R, Zhang S, Li M, Chen C, Yao Q . Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. Vaccine. 2010; 28(31):5114-27. PMC: 2906648. DOI: 10.1016/j.vaccine.2010.03.079. View

16.

Song J, Hossain J, Yoo D, Lipatov A, Davis C, Quan F . Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology. 2010; 405(1):165-75. PMC: 2925114. DOI: 10.1016/j.virol.2010.05.034. View

17.

Roldao A, Mellado M, Castilho L, Carrondo M, Alves P . Virus-like particles in vaccine development. Expert Rev Vaccines. 2010; 9(10):1149-76. DOI: 10.1586/erv.10.115. View

18.

Win S, Ward V, Dunbar P, Young S, Baird M . Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunol Cell Biol. 2011; 89(6):681-8. DOI: 10.1038/icb.2010.161. View

19.

Kaczmarczyk S, Sitaraman K, Young H, Hughes S, Chatterjee D . Protein delivery using engineered virus-like particles. Proc Natl Acad Sci U S A. 2011; 108(41):16998-7003. PMC: 3193192. DOI: 10.1073/pnas.1101874108. View

20.

El Sahly H, Davis C, Kotloff K, Meier J, Winokur P, Wald A . Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis. 2012; 205(5):703-12. PMC: 3274370. DOI: 10.1093/infdis/jir837. View